HYPERGLYCEMIA AND ADVERSE PREGNANCY OUTCOME (HAPO)

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心机构，不一定为研究者机构。这是一项由联邦政府资助的前瞻性多中心试验，旨在探讨高血糖对妊娠结局的影响（HAPO）。具体目的是在一个大型的、异质的、多国的、多文化的、种族多样的妊娠晚期妇女队列中检查葡萄糖耐量，其中医疗护理人员对葡萄糖耐量状态“不知情”，并根据母体高血糖与妊娠期糖尿病风险之间的特定关系，推导出国际上可接受的妊娠期糖尿病诊断和分类标准。不良后果。将招募妊娠早期的孕妇参与研究。提供知情同意书的受试者将提供病史和产前数据，并接受代谢评估（75 g OGTT和妊娠约28周时血红蛋白A1 C测量）。在分娩时采集脐带血，用于评估胎儿β细胞功能;在出生后1小时测定新生儿高血糖;在24小时内测量新生儿人体测量学;并记录分娩和新生儿结局数据。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a federally funded prospective multi-center trial addressing the effect of hyperglycemia on pregnancy outcome (HAPO). The specific aims are to examine glucose tolerance in a large, heterogeneous, multinational, multi-cultural, ethnically diverse cohort of women in the third trimester of gestation with medical caregivers "blinded" to status of glucose tolerance, and to derive internationally acceptable criteria for the diagnosis and classification of gestational diabetes mellitus that are based on the specific relationships between maternal hyperglycemia and the risk of specific adverse outcomes. Pregnant women will be recruited in early gestation to participate. Those who give informed consent will provide historical and antenatal data and undergo metabolic evaluation (75g OGTT and measurement of hemoglobin A1C at approximately 28 weeks gestation). Cord blood will be collected at delivery for assessment of fetal beta-cell function; neonatal hyperglycemia will be determined at one hour of life; neonatal anthropometrics measured within 24 hours; and data on delivery and neonatal outcomes will be recorded.